Abstract Library

#3460 Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Introduction: Clinical trial data show prolonged progression-free survival (PFS) with LAN in metastatic enteropancreatic NET; real-world data may demonstrate effectiveness in routine care.

Conference:

Presenting Author: Alonso T

Authors: Alonso-Gordoa T, Capdevila J, González E, Teulé A, Anido U,

Keywords: net, pancreas, lanreotide, clinical practice,

#3459 Short-term tolerability and dose toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumors (NET)

Introduction: 177Lu-DOTATATE has become a valuable treatment option in the management of advanced NET. However, PRRT treatment is usually limited by kidney toxicity, where the radiopharmaceutical is reabsorbed and retained, or bone marrow by evident hematological toxicity or in the liver.

Conference:

Presenting Author: Bonilla Plaza J

Authors: Bonilla Plaza J, Martinez Lorca A, Navarro Martinez T, Azpeitia Hernandez P, Alonso-Gordoa T,

Keywords: PRRT, 177Lu, Toxicity,

#3159 Wearables in metastatic gastroenteropancreatic neuroendocrine tumors (NETFIT)

Introduction: Patients diagnosed of an advanced neuroendocrine tumor (NET) are frequently deteriorating their quality of life due to tumor volume and growth, hormone-release related symptoms and treatment toxicity. Changes on lifestyle (exercise, nutrition and quality of sleep) of patients with solid tumors have been shown to improve treatment compliance, tolerability, as well as in quality of life. However, patients with NETs have not been included in those studies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Molina Cerrillo J, Alonso-Gordoa T, Grande E, Benavent M, Garcia-Carbonero R,

Keywords: neuroendocrine tumor, nutritional and exercise assessment, quality of life, trial in progress,